All In Biotech

Drug Trial Radar · NCT05348785

A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 650 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

650

Actual

Start

Apr 19, 2022

Primary completion

Mar 9, 2026

Study completion Mar 9, 2026

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
Denali Therapeutics Inc.
First posted
Apr 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, researchers will learn more about BIIB122 in participants with early-stage Parkinson's disease (PD). The study will include adults aged 30 to 80 who were diagnosed with PD within 2 years of starting the study. The main objective of the study is to learn about the effect BIIB122 has on slowing down the worsening of PD symptoms. The main question researchers want to answer is: \- How long does it take for PD symptoms to worsen during BIIB122 treatment? Researchers will answer this and other questions by measuring the symptoms of PD over time using a variety of scoring tools. These include the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the modified Schwab and England Activities of Daily Living Scale (mSE-ADL). The MDS-UPDRS is used to measure symptoms of PD. It has 4 parts: Part I, II, III, and IV. Each part measures different aspects of motor and non-motor symptoms. The mSE-ADL measures a participant's ability to perform daily activities or personal chores. Researchers will also learn more about the safety of BIIB122. They will check participants for adverse events. Adverse events are unwanted health problems that may or may not be caused by the study drug. The study will be done as follows: * Participants will be randomly assigned to take either BIIBB122 or placebo. A placebo looks like the study drug but contains no real medicine. * Neither the researchers nor the participants will know if the participants are receiving BIIB122 or placebo. * Participants will take BIIB122 or placebo tablets by mouth once a day. * The treatment period for each participant will last between 48 and 144 weeks. * There will be a safety follow-up period for 2 weeks after the last dose of BIIB122. * In total, participants will have up to 29 study visits. * Participants will stay in the study for at least 1 year, up to about 3 years.

Conditions

  • Parkinson Disease

Interventions

  • BIIB122Drug

    Administered as specified in the treatment arm

  • BIIB122-Matching PlaceboDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Confirmed Worsening in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score Over the Treatment PeriodTime frame: Up to Week 144

Locations

113 sites in 13 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Banner Sun Health Research Institute

    Sun City, Arizona

  • University of Southern California

    Los Angeles, California

  • Cedars Sinai

    Los Angeles, California

  • SC3 Research Group Inc.

    Pasadena, California

  • University of California San Francisco (UCSF)

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • CenExel Rocky Mountain Clinical Research

    Englewood, Colorado

  • Invicro

    New Haven, Connecticut

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • University of Miami

    Miami, Florida

  • Adventist Health System/Sunbelt, Inc.

    Orlando, Florida

  • USF Health Byrd Institute

    Tampa, Florida

  • Hawaii Pacific Neuroscience, LLC

    Honolulu, Hawaii

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas

  • Boston University Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Quest Research Institute

    Farmington Hills, Michigan

  • Mount Sinai Beth Israel

    New York, New York

  • Weill Medical College of Cornell University

    New York, New York

  • Duke Movement Disorders Clinic

    Durham, North Carolina

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • UPHS

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Neurology Clinic, PC

    Cordova, Tennessee

  • The Methodist Hospital Research Institute

    Houston, Texas

  • Central Texas Neurology Consultants

    Round Rock, Texas

  • Virginia Commonwealth University Department of Neurology

    Richmond, Virginia

  • Evergreen Hospital Medical Center

    Kirkland, Washington

  • Inland Northwest Research

    Spokane, Washington

  • Klinik Ottakring

    Vienna, Austria

  • Medizinische Universität

    Innsbruck, Tyrol, Austria

  • University of Calgary

    Calgary, Alberta, Canada

  • True North Clinical Research

    Halifax, Nova Scotia, Canada

  • Toronto Western Hospital

    Toronto, Ontario, Canada

  • CHUM Centre de Recherche

    Montreal, Quebec, Canada

  • Montreal Neurological Institute

    Montreal, Quebec, Canada

Showing 40 of 113 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.